Trade Name Generic Name Dosage

Classification Action

Indication

Contraindication

Dinoprostone Prostin E, Prepidil, Cervidil Intravaginal administration  Cervidil = Intracervical gel  Prostin E2 = Intravaginal suppository The dosage of dinoprostone in the vaginal insert is 10 mg designed to be released at approximately 0.3 mg/hour over a 12 hour period. Cervidil should be removed upon onset of active labor or 12 hours after insertion. Uterine Stimulants, Abortifacient, Prostaglandin  Prostaglandin E2  Uterine and gastrointestinal smooth muscle stimulation  Cervical softening and dilation  Increases frequency and strength of uterine contraction. Cervidil Vaginal Insert (dinoprostone, 10 mg) is indicated for the initiation and/or continuation of cervical ripening in patients at or near term in whom there is a medical or obstetrical indication for the induction of labor. Endocervically administered dinoprostone gel is not recommended for the following:  Patients in whom oxytocic drugs are generally contraindicated or where prolonged contractions of the uterus are considered inappropriate, such as: o Cases with a history of cesarean section or major uterine surgery. o Cases in which cephalopelvic disproportion is present. o Cases in which there is a history of difficult labor and/or traumatic delivery. o Grand multiparae with 6 or more previous term pregnancies cases with nonvertex presentation. o Cases with hyperactive or hypertonic uterine patterns. o Cases of fetal distress where delivery is not imminent. o In obstetric emergencies where the benefit-to-risk ratio for either the fetus or the mother favors surgical intervention.  Patients with hypersensitivity to prostaglandins

water bath. Acute pelvic inflammatory disease. Monitor uterine tone and vaginal discharge throughout the procedure and several days after procedure. diarrhea Fever Orthostatic hypotension Arrhythmia Store suppositories in freezer and bring to room temperature before insertion. microwave) Ensure adequate hydration throughout the procedure. Vaginal Suppository Hypersensitivity to dinoprostone. pulmonary. Give oxytocin 6-12 hours after dinoprostone. Patients with active cardiac. . Do not force warming with external sources (ie. Store cervical gel in freezer and bring to room temperature in room temperature. Patients with placenta previa or unexplained vaginal bleeding during this pregnancy. renal. just prior to use.      Adverse Reaction       Nursing Responsibilities    or constituents of the gel. or hepatic disease. Patients for whom vaginal delivery is not indicated. Nausea and vomiting. such as vasa previa or active herpes genitalia. Be prepared to support patient through labor (cervical ripening).

V. toxemia of pregnancy (PIH)  Nausea. use may induce sudden hypertension and cerebrovascular accidents. Methylergonovine Methylergonovine maleate PO = 0. prolonged contractions  Not for induction of labor (intense uterine activity) Prevention and treatment of postpartum and postabortion hemorrhage caused by uterine atony or subinvolution  contraindicated in patients hypersensitive to methylergonovine or any component of the formulation. I.  hypertension. abdominal cramping  Hypertension  Be alert for adverse reactions and drug interactions.Trade Name Generic Name Dosage Classification Action Indication Contraindication Adverse Reaction Nursing Responsibilities Methergine.2 mg q 2 – 4 H (max 5 doses) Uterine Stimulants  Directly stimulate uterine contractions o Small doses = with normal resting muscle tone o Intermediate doses = more forceful and prolonged contractions with elevated resting muscle tone o Large doses = severe. slowly over several minutes and monitor blood pressure closely. As a last resort. give I. azole antifungals. Methylergobrevin.  This drug should be used extremely carefully because of its potent vasoconstrictor action. and some macrolide antibiotics). IM = 0.V.  Monitor Uterine Contractions . Methylergobasine.2 mg q 6-8 H (max 1 week).  ergot alkaloids are contraindicated with potent inhibitors of CYP3A4 (includes protease inhibitors. vomiting.

coma from water intoxication  Gastrointestinal: Nausea. and cardiac output. abruption placentae. heart rate.  Also contraindicated in cephalopelvic disproportion or delivery that requires conversion.  Have 20% solution magnesium sulfate available for relaxation of the myometrium. seizures. vomiting. hypertonic uterine patterns. pelvic hematoma  Hematologic: afibrinogenemia  Respiratory: anoxia. fetal heart rate. asphyxia  Monitor and record uterine contractions. and coma  Never give oxytocin simultaneously by more than one route. total placenta previa or vasa previa. in prematurity and in severe toxemia. in fetal distress when delivery isn’t imminent.  Cardiovascular: hypertension. impaired uterine blood flow.Trade Name Generic Name Dosage Classification Action Indication Contraindication Adverse Reaction Nursing Responsibilities Pitocin. systemic venous return. blood vessels and mammary glands  Third trimester = active labor Induction of labor at term. adjunctive therapy in management of abortion  Contraindicated in patients hypersensitive to the drug or any of its component. increased heart rate. BP. intrauterine pressure. Syntocinon Oxytocin  For stimulation of labor: 10 units (1ml) of drug infused in 1L D5LRS before deliver  For Reduction of Postpartum bleeding: 1 amp after delivery of placenta Uterine Stimulants  Stimulates the smooth muscles of uterus. and arrhytmias  CNS: seizures. and blood loss q15. . Antidiuretic effect may lead to fluid overload.  GU: titanic uterine contractions.  Be alert for adverse reaction  Monitor I/O. control of postpartum bleeding. as in tranverse lie.  Also contraindicated in fetal distress.

agranulocytopenia  Metabolic: weight gain. Apresoline Hydralazine 5 mg/dose then 5-10 mg every 20-30 minutes as needed. but to call the one who prescribed it if adverse reaction occurs. palpitations. (TIV)  Hydralazine ↓ Directly relaxes arteriolar smooth muscle ↓ Vasodilaion ↓ Lowers Blood Pressure Pre-eclampsia /eclampsia  Contraindicated to pt.  Tell pt. if they’re above 50mm Hg . CVA. or severe renal impairment. and notify physician or midwife. arrythmias. anorexia  Hematologic: neutropenia.Trade Name Generic Name Dosage Classification Action If contractions are less than 2 minutes apart. angina. and in those taking other antihytensives. headache. dizziness  CV: orthostatic hypotension. diarrhea. Indication Contraindication Adverse Reaction Nursing Responsibilities .  CNS: peripheral neuritis.  Tell client to limit sodium intake.s hypersensitive to the drug and any of its component and in those with coronary artery disease or mitral valvular rheumatic heart disease. sodium retention  Skin: rash  Assess blood pressure before starting therapy and regularly thereafter. or longer.  Inform client that orthostatic hypotension can be minimized by rising slowly and not changing position suddenly.  Instruct client to take oral form with meals. leukopenia.  GI: n/v.  Use cautiously in patients with suspected cardiac disease.or if they last 90sec. tachycardia. not to abruptly stop taking drug. and turn patient on her side. stop infusion.

milk. pyridoxine-responsive anemia. nausea. coffee. Use in those with normal iron balance. and cirrhosis of the liver. regional enteritis. and ulcerative colitis. hemochromatosis. . Hemosiderosis. Hemolytic anemia. or tea consumed with a meal or 1 hr after may significantly inhibit absorption of dietary iron. peptic ulcer. anorexia.Trade Name Generic Name Dosage Classification Action Indication Contraindication Adverse Reaction Nursing Responsibilities Ferrous Sulfate Ferrous Sulfate (FeSO4) 200mg/day PO Antianemic.  Eggs. diarrhea. iron absorption is not decreased if calcium carbonate is used and taken between meals. dark colored stools.  Ingestion of calcium and iron supplements with food can decrease iron absorption by one-third.  Substitution of one iron salt for another without proper adjustment may result in serious over or under dosing.  Dietary supplement for iron. Iron Males: 12-20mg Females: 8-15mg Iron is absorbed from the duodenum and upper jejunum by an active mechanism through the mucosal cells where it combines with the protein transferrin. gastric irritation. abdominal cramps. Constipation.  Do not crush or chew sustained-release products. Optimum therapeutic responses are usually noted within 2-4 weeks.  Prophylaxis and treatment of iron deficiency and iron-deficiency anemias.

respiratory depression Pregnancy safety: Magnesium sulfate is administered to treat toxemia of pregnancy. IV calcium gluconate or calcium chloride should be available as an antagonist to magnesium if needed. analgesics. and alcohol  Neuromuscular blocking agents = concurrent use with MgSO4 will further depress muscular activity. blood pressure. Convulsions may occur up to 48 hr after delivery. Low Amount of Calcium in the Blood  Allergies:Magnesium Magnesium Sulfate  Deep tendon reflexes = absent  Decreased urine output  Decreases respiratory rate. Serious Kidney Problems. The . maintenance dose (1 – 3 g per hour by continuous infusion) CNS depressant  CNS depressants = potentiate CNS depressant effects of MgSO4 (barbiturates. tranquilizers.Trade Name Generic Name Dosage Classification Action Indication Contraindication Adverse Reaction Nursing Responsibilities Magnesium sulfate Magnesium sulfate  Anticonvulsant: o IM = loading dose (10 g of 50% solution [20 mL] divided into 2 doses). if possible. alternate buttocks o IV = loading does (4 g MgSO4 in 250 mL of D5W infuse at 10 mL per minute. High Amount of Magnesium in the Blood. maintenance dose (4 – 5 g of 50% solution [10 mL] q4H deep IM. Seizures of eclampsia (toxemia of pregnancy)  Conditions:Kidney Disease. fetal heart rate (fetal distress)  Confusion  Neonates = hypotension. necessitating continued therapy. It is recommended that the drug not be administered in the 2 hours before delivery. general anesthetics. maintenance dose (1 – 2 g per hour by continuous infusion)  Preterm labor: IV = loading dose (4 g of MgSO4 over 15 – 30 minutes. hyporeflexia.

comatose patient. pulse and respiratory rate frequently. antihistamines. Derm: photosensitivity. Magnesium must be used with caution in patients with renal failure. Prophylactic administration of magnesium sulfate for patients with acute mvocardial infarction should be considered. fatigue.Trade Name Generic Name Dosage Classification Action Indication Contraindication Adverse Reaction Nursing Responsibilities "cure" for toxemia is delivery of the baby.  Do not give rectal supp or tabs to children younger than 2 years old because of risk of fetal respiratory depressions  Give IM injections deep into muscle  Do not administer SQ. adjunct to anesthesia and analgesia. bladder neck obstruction. diplopia. dry mouth. tinnitus. blocks cholinergic receptors in the vomiting center that are believed to mediate the nausea and vomitting caused by gastric irritation.  Assess patient for nausea and vomiting before and after administration. rashes. hypotension.  Assess level of sedation after administration.  CV: bradycardia. disorientation. mucus production. prostatic hypertrophy.  Hema: blood dyscrasias  Monitor BP. dizziness. sedation. confusion. nervousness. sedative/hypnotics Selectively blocks H1 receptors. hypertension. since it is cleared by the kidneys and can reach toxic levels easily in those patients.  EENT: blurred vision. tissue necrosis may . extrapyramidal reaction. tachycardia. narrow angle glaucoma  CNS: neuroleptic malignant syndrome. itching and tearing that accompany allergic reactions. treatment and prevention of nausea and vomiting. Phenergan promethazine HCI 25-50 mg (sedation).  Administer each 25mg slowly over at least 1 hr. drug-induced hepatitis. Preoperative sedation. Hypersensitivity. diminishing the effects of histamine on cells of the upper respiratory tract and eyes and decreasing the sneezing. 10-25mg q 4hr as needed (antiemetic) (1amp) anti-emetics.  GI: constipation. insomnia.

Infiltration and Nerve Blocker Lidocaine ↓ Stabilizes the neuronal membrane ↓ Inhibits sodium ion movemnts ↓ Conduction of impulses are inhibited ↓ Local loss of pain sensation  Injected prior to normal spontaneous delivery to anesthetize the area of the perineum to be used for episiotomy.  Trade Name Generic Name Dosage occur Arteriospasms and gangrene of artery may occur when administered intra-arterially.6ml1ml) of a 1.5ml) of a 5% hyperbaric solution.  For Cesarean Section: Up to 75 mg (1. Classification Action Indication Contraindication Adverse Reaction Nursing Responsibilities Xylocaine Lidocaine  For normal vaginal delivery: 50mg/ml of a 5% hyperbaric solution or 9mg-15mg (0. Reduce dosage of barbiturates given concurrently within promethazine by least half. depressed respiration.5% solution. . or seizures.  Used as a local anesthesia for Cesarean section  Hypovolemia  Heartblock  Other Conduction Disturbances  Dizziness  Paresthesia  Drowsiness  Confusion  Respiratory Depression  Convulsions Observe for untoward reactions such as drowsiness.

blurred vision. asthma. Contraindicated in patients with angle-closure glaucoma. ↓ Promotes cervical effacement To reduce secretions perioperatively. & unstable CV. headache. intestinal atony. COPD.Trade Name Generic Name Dosage Classification Action Buscopan Hyoscine Butylbromide Given via IV. Hyoscine Butylbromide ↓ Inhibits muscarinic actions of acetylcholine in the ANS ↓ Affecting neural pathway ↓ Relieves spasticity. urinary retention  Skin: rash. irritability. photophobia.  CNS: dizziness. 1mg/ml to promote cervical effacement. tachycardia. nausea. restlessness. Indication Contraindication Adverse Reaction Nursing Responsibilities . reduces secretions. disorientation. dysphagia  GU: urinary hesitancy. flushing  EENT: dilated pupils. and blocks cardiac vagal reflexes. vomiting  CV: palpitations. myasthenia gravis. paralytic ileus.  Monitor cervical effacement and dilatation. nausea and vomitting.  Encourage pt. dryness  Be alert for adverse reactions and drug interactions. fever  GI: constipation. obstructive uropathy. dry mouth. to void  Monitor BP for possible hypotension.

jaundice. particularly in meningitis. hyperglycemia. elevated BUN. anorexia. Furomide .i. oral and gastric burning. vomiting.  Metabolic: Hypovolemia. and kidney disease.Trade Name Generic Name Dosage Classification Action Indication Contraindication Adverse Reaction Fumide . circulatory collapse. decreases renal vascular resistance and may increase renal blood flow Treatment of edema associated with CHF.  CV: Postural hypotension. acute hypotensive episodes. History of hypersensitivity to furosemide or sulfonamides. Exact mode of action not clearly defined. loop diuretic Rapid-acting potent sulfonamide "loop" diuretic and antihypertensive with pharmacologic effects and uses almost identical to those of ethacrynic acid.  GI: Nausea. increasing oliguria. hypomagnesemia. fluid and electrolyte depletion states. hyperuricemia. and for treatment of hypercalcemia. hepatic coma. dizziness with excessive diuresis. hypochloremia metabolic alkalosis. hyponatremia hypokalemia. hypocalcemia (tetany). May be used for management of hypertension. Has been used concomitantly with mannitol for treatment of severe cerebral edema. alone or in combination with other antihypertensive agents. cirrhosis of liver. Luramide FUROSEMIDE (fur-oh'se-mide)  Edema Adult: PO 20–80 mg in 1 or more divided doses up to 600 mg/d if needed IV/IM 20–40 mg in 1 or more divided doses up to 600 mg/d  Hypertension Adult: PO 10–40 mg b. including nephrotic syndrome.  Urogenital: Allergic interstitial nephritis. dehydration. pregnancy (category C). glycosuria. Lasix.d. acute pancreatitis. (max: 480 mg/d) Electrolytic and water balance agent. abdominal cramping. constipation. anuria. . lactation. diarrhea.

Report decrease or unusual increase in output. and hypotension. thrombophlebitis. Sudden death from cardiac arrest has been reported. Excessive diuresis can result in dehydration and hypovolemia. CO2.  Monitor BP during periods of diuresis and through period of dosage adjustment.  Hematologic: Anemia. feeling of fullness in ears. blood sugar.  Body as a Whole: Increased perspiration. urinary frequency. exfoliative dermatitis. Assessment & Drug Effects  Observe patients receiving parenteral drug carefully. closely monitor BP and vital signs.Nursing Responsibilities irreversible renal failure. BUN. Weigh patient daily under standard conditions. aplastic anemia. muscle spasms. thrombocytopenic purpura.  Monitor urine and blood glucose & HbA1C closely in diabetics and patients with decompensated hepatic cirrhosis. Drug may cause hyperglycemia.  Monitor for S&S of hypokalemia. hearing loss (rarely permanent). vertigo. leukopenia. necrotizing angiitis (vasculitis).  Observe older adults closely during period of brisk diuresis. pain at IM injection site. Report symptoms to physician. purpura. blurred vision. agranulocytosis (rare).  Special Senses: Tinnitus.  Skin: Pruritus. photosensitivity. Sudden alteration in fluid and electrolyte balance may precipitate significant adverse reactions. urticaria. weakness.  Lab tests: Obtain frequent blood count. paresthesias. .  Monitor I&O ratio and pattern. activation of SLE. porphyria cutanea tarde. serum and urine electrolytes. and uric acid values during first few months of therapy and periodically thereafter. circulatory collapse.

drowsiness.  Aids in the induction of anesthesia and as part of balanced anesthesia. repositioning and vasopressors.  Monitor BP. hiccoughs. laryngospasm.  If overdose occurs. oversedation.08 mg/kg  Therapeutic: Anti-anxiety agents. and BP continuously.  Effects may be mediated by GABA. vomiting. dyspnoea. treatment includes IV fluids. hallucination. Maintain patent airway and assist ventilation as needed. Hypnovel.  Assess level of sedation and level of consciousness throughout and for 2-6 hr following administration. monitor pulse. Hypersensitivity to benzodiazepines. sedative/hypnotics  Pharmacologic: benzodiazepines Physiologic Mechanism:  Short-term sedation  Postoperative amnesia Pharmacologic Mechanism:  Acts at many levels of the CNS to produce generalized CNS depression. If hypotension occurs. headache.07-0. an inhibitory neurotransmitter. amnesic episodes. ataxia.Trade Name Generic Name Dosage Classification Action Indication Contraindication Adverse Reaction Nursing Responsibilities Dormicum. paradoxical reactions. Chronic respiratory insufficiency. respiration . pulse and respiration continuously during IV administration. nausea.  The effects of midazolam can be reversed with . and Versed Midazolam IV: inject 2.  Preprocedural sedation. Oxygen and resuscitative equipment should be immediately available. rash.5 mg for 2 minutes (never as bolus) IM: 0. Rarely cardioresp adverse events.

stiff-man syndrome. Valium. tardive dyskinesia. E-Pam .  CNS: Drowsiness.i. vertigo. paraplegia.  Body as a Whole: Throat and chest pain. Diazemuls . to q.flumazenil (Romazicon).d.d. Management of anxiety disorders. to allay anxiety and tension prior to surgery. voiding problems in older adults. it appears to act at both limbic and subcortical levels of CNS.d. Meval . Diastat. amnesia. dizziness. for short-term relief of anxiety symptoms. Trade Name Generic Name Dosage Classification Action Indication  Contraindication Apo-Diazepam. repeat if needed in 3–4 h Geriatric: PO 1–2 mg 1–2 times/d (max: 10 mg/d) Child: PO >6 mo. ataxia. or t. confusion. slurred speech.5 mg b. EEG changes. athetosis. Central nervous system agent. with somewhat shorter duration of action. and adjunctively for relief of skeletal muscle spasm associated with cerebral palsy. Drug of choice for status epilepticus. anxiolytic Psychotherapeutic agent related to chlordiazepoxide. benzodiazepine anticonvulsant. cardioversion and endoscopic procedures.i. and treatment for restless legs.i. . or 15–30 mg/d sustained release IV/IM 2–10 mg. 1–2. repeat if needed at 10– 15 min intervals up to 30 mg. Valrelease. paradoxic rage. tetanus. Also used to alleviate acute withdrawal symptoms of alcoholism. headache. Like chlordiazepoxide. vivid dreams. then repeat if needed q2–4h  Withdrawal Adult: PO 2–10 mg b. fatigue. Novodipam . reportedly superior in antianxiety and anticonvulsant activity. tremor. as an amnesic. Vivol DIAZEPAM (dye-az'e-pam)  Status Epilepticus Adult: IV/IM 5–10 mg.d.i.

diplopia. patient tolerance to therapeutic effects may develop after 4 wk of treatment. Assessment & Drug Effects  Monitor for adverse reactions. Physician will rely on accurate observation and reports of patient response to the drug to determine lowest effective maintenance dose. acute narrow-angle glaucoma. Tablet form: Infants <6 mo of age. phlebitis at injection site.  Monitor for therapeutic effectiveness. edema. laryngospasm. Maximum effect may require 1–2 wk. infants <30 d of age. Safe use during pregnancy (category D) and lactation is not established.  Special Senses: Blurred vision. Most are dose related. gynecomastia (prolonged use). venous thrombosis. Injectable form: Shock. including urinary and bowel elimination. nystagmus.  Monitor I&O ratio.  GI: Xerostomia. muscular weakness. Dosage adjustment may be necessary. ovulation failure. acute alcohol intoxication. Other: Pain. depressed vital signs.  Observe necessary preventive precautions for suicidal tendencies that may be present in anxiety states accompanied by depression. cardiovascular collapse. hepatic dysfunction.  Urogenital: Incontinence. coughing. and respiratory depression may occur. Adverse reactions such as drowsiness and ataxia are more likely to occur in older adults and debilitated or those receiving larger doses. obstetrical patients. tachycardia. coma. urinary retention. untreated openangle glaucoma.  Observe patient closely and monitor vital signs when diazepam is given parenterally. nausea.Adverse Reaction Nursing Responsibilities CV: Hypotension. hypotension. during or within 14 d of MAO inhibitor therapy. menstrual irregularities.  Supervise ambulation.  . constipation.  Lab tests: Periodic CBC and liver function tests during prolonged therapy.  Respiratory: Hiccups. tachycardia.

biliary. fatigue. anxiety  CV: transient hypertension  GI: nausea. Reglan Metoclopramide Antiemetic.  relief of symptoms of acute and recurrent diabetic gastroparesis  -short.Trade Name Generic Name Dosage Classification Action Plasil. insomnia. has sedative properties. or pancreatic secretions. accelerates gastric emptying and intestinal transit. relaxes pyloric sphincter. pregnancy  CNS: restlessness. GI stimulant Stimulates motility of upper GI tract without stimulating gastric. appears to sensitize tissues to action of acetylcholine. induces release of prolactin. when combined with effects on motility. lactation. GI hemorrhage.term therapy for adults with GERD  parenteral: prevention of nausea and vomiting  prophylaxis of postoperative nausea and vomiting when nasogastric suction is undesirable  treatment of nausea and vomiting of a variety of etiologies  contraindicated with allergy to metoclopramide. increases lower esophageal sphincter pressure. epilepsy. diarrhea  monitor BP carefully during IV administration  keep diphenhydramine injection readily available in case extrapyramidal reactions occur Indication Contraindication Adverse Reaction Nursing Responsibilities . Maxolon. little effect on gallbladder or colon motility.  use cautiously with previously detected breast cancer. mechanical obstruction or perforation. drowsiness. which. dizziness.

report involuntary movement of the face. increased intracranial pressure.nervousness. 20mg/ml Narcotic agonist-antagonist analgesic Nalbuphine acts as an agonist at specific opioid receptors in the CNS to produce analgesia. tingling. hostility. bradycardia. vertigo. as a supplement to surgical anesthesia. sedation but also acts to cause hallucinations and is an antagonist at µ receptors Relief of moderate to severe pain  Preoperative analgesia. pregnancy prior to labor. tachycardia  DERMATOLOGIC: Itching. euphoria. laboror delivery. dysphoria. anoxia.  CNS: Sedation.dyspepsia. unusual dreams. respiratory depression. and limbs Trade Name Generic Name Dosage Classification Action Indication Contraindication Adverse Reaction Nubain Nalbuphine Hydrochloride Injection – 10 mg/ml. restlessness.depression crying. clamminess. dizziness. bitter taste. or sedatives can cause serious sedation. acute MI when nausea and vomiting are present. numbness. Hypertension. COPD. cramps.  CV: Hypotension. confusion.    have phenotolamine readily available in case of hypertensive crisis take drug exactly as prescribed use of alcohol. blurred vision. hallucinations. burning. sleep remedies. flushing.vomiting. headache. urticaria  GI: Nausea. sulfites. unreality. feeling of heaviness. dry mouth .  Use cautiously with emotionally unstable clients or those with a history of narcotic abuse.floating feeling. warmth. lactation. eyes. and for obstetric analgesia during labor and delivery Hypersensitivityto nalbuphine. sweating. faintness. biliary tract surgery. bronchial asthma.

or are undergoing tooth extraction orother oral surgical procedures. Tranexamic acid is used for the prompt and effective control of hemorrhage in various surgical and clinical areas:  Treating heavy menstrual bleeding  Hemorrhage following dental and/or oral surgery in patients with hemophilia  Management of hemophilic patients (those having Factor VIII or Factor IX deficiency) who have oral mucosal bleeding.  Obstetrical and gynecological: abortion. By inhibiting the action of plasmin (finronolysin) the antifibrinolytic agents reduce excessive breakdown of fibrin and effect physiological hemostasis. Fibrinon. Cyklokapron. antihemorrhagic Tranexamic acid is a synthetic derivative of the amino acid lysine. in the leg. dyspnea. brain). Lysteda. lung. Anti-fibrinolytic drug inhibits endometrial plasminogen activator and thus prevents fibrinolysis and the breakdown of blood clots. asthma Monitor respiratory rate before and after giving nubain because it causes respiratory depression Monitor I and O to determine if there is excessive fluid loss Monitor Bp before and after administering the medication to prevent any complication Trade Name Generic Name Dosage Classification Action Hemostan. have a historyof blood clots.  Allergic reaction to the drug or hypersensitivity  Presence of blood clots (eg. The plasminogen-plasmin enzyme system is known to cause coagulation defects through lytic activity on fibrinogen. It exerts its antifibrinolytic effect through the reversible blockade of lysine-binding sites on plasminogen molecules. postpartum hemorrhage and menometrorrahgia.  Nursing Responsibilities    GU: Urinary urgency RESPIRATORY: Respiratory depression. Transamin Tranexamic Acid Anti-fibrinolytic. or are Indication Contraindication . fibrin and other clotting factors. eye.

Do not take 2 doses at once.  The medication can be taken with or without meals. . then take your next dose at least 6 hours later.or chew before swallowing. swelling or tenderness* Chest pain* Confusion* Coughing up blood* Decreased urination* Severe or persistent headache* Severe or persistent body malaise* Shortness of breath* Slurred speech* Slurred speech* Vision changes  Unusual change in bleeding pattern should be immediately reported to the physician.  Tranexamic Acid should be used with extreme caution in CHILDREN younger than 18 years old.  If you miss a dose of Tranexamic Acid. crush. the medication should only be taken during the menstrual period. dyspnea. hives. face. Do not break.Adverse Reaction Nursing Responsibilities at risk for blood clots  Current administration of factor IX complex concentrates or anti-inhibitorcoagulant concentrates Severe allergic reactions such as rash. take it when you remember. safety and effectiveness in these children have not been confirmed. lips or tongue* Calf pain. itching. swelling of the mouth.  Swallow Tranexamic Acid whole with plenty of liquids.  For women who are taking Tranexamic acid to control heavy bleeding. tightnessin the chest.

Sign up to vote on this title
UsefulNot useful